Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pembrolizumab versus investigator-choice chemotherapy for MSI-H/dMMR metastatic colorectal cancer
MOH_2017-06-11_000508Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in colorectal cancer (CRC) (2 arms), sponsored by Merck & Co. Started Nov 2015; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2017-06-11_000508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-11_000508.